Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2, Single Arm Study Of Ticilimumab In Patients With Refractory Metastatic Adenocarcinoma Of The Colon Or Rectum

NCT00313794 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT00313794
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00313794 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2, Single Arm Study Of Ticilimumab In Patients With Refractory Metastatic Adenocarcinoma Of The Colon Or Rectum
Lead sponsor
AstraZeneca
Phase
Phase 2
Overall status
Completed
Start date
May 31, 2006
Completion date
June 30, 2008
Enrollment
49 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

colorectal neoplasms